• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of biochemjBJ Latest papers and much more!
Biochem J. Mar 15, 2006; 394(Pt 3): 647–656.
Published online Feb 24, 2006. Prepublished online Oct 24, 2005. doi:  10.1042/BJ20050737
PMCID: PMC1383714

Plasma-membrane-associated sialidase (NEU3) differentially regulates integrin-mediated cell proliferation through laminin- and fibronectin-derived signalling

Abstract

We have found previously that human plasma-membrane-associated sialidase (NEU3), a key glycosidase for ganglioside degradation, was markedly up-regulated in human colon cancers, with an involvement in suppression of apoptosis. To elucidate the molecular mechanisms underlying increased NEU3 expression, in the present study we investigated its role in cell adhesion of human colon cancer cells. DLD-1 cells transfected with NEU3 exhibited increased adhesion to laminins and consequent cell proliferation, but decreased cell adhesion to fibronectin and collagens I and IV, compared with control cells. When triggered by laminins, NEU3 clearly stimulated phosphorylation of FAK (focal adhesion kinase) and ERK (extracellular-signal-regulated kinase), whereas there was no activation on fibronectin. NEU3 markedly enhanced tyrosine phosphorylation of integrin β4 with recruitment of Shc and Grb-2 only on laminin-5, and NEU3 was co-immunoprecipitated by an anti-(integrin β4) antibody, suggesting that association of NEU3 with integrin β4 might facilitate promotion of the integrin-derived signalling on laminin-5. In addition, the promotion of phosphorylation of integrin β1 and ILK (integrin-linked kinase) was also observed on laminins. GM3 depletion as the result of NEU3 overexpression, assessed by TLC, appeared to be one of the causes of the increased adhesion on laminins and, in contrast, of the decreased adhesion on fibronectin – NEU3 probably having bimodal effects. These results indicate that NEU3 differentially regulates cell proliferation through integrin-mediated signalling depending on the extracellular matrix and, on laminins, NEU3 did indeed activate molecules often up-regulated in carcinogenesis, which may cause an acceleration of the malignant phenotype in cancer cells.

Keywords: fibronectin, ganglioside, integrin, laminin-5, NEU3, sialidase
Abbreviations: BrdU, bromodeoxyuridine; ECM, extracellular matrix; EHS, Engelbreth–Holm–Swarm tumour; ERK, extracellular-signal-regulated kinase; FAK, focal adhesion kinase; FBS, fetal bovine serum; HA, haemagglutinin; HGF, hepatocyte growth factor; HRP, horseradish peroxidase; ILK, integrin-linked kinase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide

INTRODUCTION

Cell interactions with the ECM (extracellular matrix) is crucial for essential biological processes such as adherence, migration, proliferation and differentiation, as well as survival [1,2]. Alterations in ECM components and the integrin family of receptors have been observed in various cancers [3,4], but their specific roles and regulatory mechanisms remain largely unclear. Ganglioside sialic-acid-containing glycosphingolipids present in cell-surface membranes are thought to make important contributions to cell-surface interactions and transmembrane signalling [5]. Altered sialylation of glycosphingolipids is observed in cancer as a ubiquitous phenotype, leading to the appearance of tumour-associated antigens, aberrant adhesion and blocking of transmembrane signalling [6]. Several reports have provided evidence that gangliosides are involved in cell adhesion to ECM through modulation of integrin functions. Ganglioside GM3 is required for adhesion of FUA169 cells to fibronectin through integrin α5β1 functions [7], promoting interactions of integrin α3 with tetraspanin CD9 in microdomains [8], and inhibiting the association of EGFR (epidermal growth factor receptor) with integrin β1 [9] and of integrin α5β1 with MMP-9 (matrix metalloproteinase-9) [10].

Gangliosides are metabolically regulated by the functional balance between sialidases and sialyltransferases that are responsible for their degradation and synthesis respectively. To understand the pathological significance of aberrant alterations of gangliosides in cancer, we have been focusing on sialidases of mammalian origin. The four forms, abbreviated to Neu1, Neu2, Neu3 and Neu4 [11,12], differ in their major subcellular localizations and substrate specificities, although their functional roles are not fully understood. Plasma-membrane-associated sialidase (Neu3) is a key enzyme for ganglioside hydrolysis. To obtain functional evidence regarding Neu3, we cloned and characterized sialidase cDNAs of mammalian origin previously [1315]. In the present study we have employed a human orthologue NEU3 cDNA [14].

Consistent with the frequent aberrant expression of gangliosides in cancer, we have demonstrated previously [16] a remarkable up-regulation of the human plasma-membrane-associated sialidase (NEU3) in colon cancers. Because of its unique character in specifically hydrolysing gangliosides at plasma membranes, it is likely to participate in cell-surface events through modulation of gangliosides. To shed light on the molecular mechanisms underlying the increased expression of NEU3 in colon cancer, in the present study we investigated the influence of NEU3 on integrin-mediated signalling in colon cancer cells and found promotion of cell adhesion and integrin signalling on laminins, but opposite effects on fibronectin, which could be of advantage to the progression of colon carcinoma cells.

EXPERIMENTAL

ECMs and antibodies

Laminin from EHS (Engelbreth–Holm–Swarm tumour) and fibronectin from human plasma were purchased from Asahi Techno Glass. Laminin from human placenta was obtained from Sigma. Human recombinant laminin-5 was prepared and purified as described previously [17]. Neutralizing antibodies to integrins α3 (ASC-1), α6 (GoH3), β1 (6S6) and β4 (ASC-8; Chemicon) were used for adhesion inhibition assays and flow cytometric analyses. An antibody to integrin β4 (3E1) for immunoprecipitation and stimulation was also obtained from Chemicon. HRP (horseradish peroxidase)-conjugated anti-(mouse IgG1) antibodies, antibodies to integrin β1 for immunoprecipitation (MAR4) and immunoblotting (clone18) respectively, and antibodies to phosphotyrosine (PY20) and Shc, were obtained from BD Biosciences. Antibodies to FAK (focal adhesion kinase), integrin β4 and the transferrin receptor were obtained from Santa Cruz Biotechnology. The anti-phosphoserine antibody was from Sigma. Antibodies to phospho-threonine, phospho-ERK (Thr202/Tyr204; where ERK is extracellular-signal-regulated kinase), ERK, phospho-FAK (Tyr925) and phospho-Shc (Tyr317) were from Cell Signaling Technology. Antibodies to phospho-FAK (Tyr397) and ILK (integrin-linked kinase) were purchased from Upstate. The HRP-conjugated anti-(rat IgG) antibody was from Jackson Immuno-Research Laboratories. FITC-conjugated anti-(mouse Ig) and anti-(rat Ig) antibodies were obtained from Biosource; anti-HA (haemagglutinin) antibodies were from Roche Diagnostics; and monoclonal anti-GM3 antibodies (M2590) were from Nippon Biotest Laboratory. A monoclonal anti-NEU3 antibody, prepared as described previously [18], was subjected to HRP conjugation and was used for detection of endogenous NEU3.

Cell culture and NEU3 transfection

Human colon adenocarcinoma-derived DLD-1 cells (Health Science Research Sources Bank, Osaka, Japan), HCT-116 cells (A.T.C.C.) and Colo 205 cells (Cancer Cell Repository, Tohoku University, Sendai, Japan) were maintained at 37 °C with 5% CO2 in RPMI 1640 containing 10% (v/v) FBS (fetal bovine serum). Cell-culture dishes and plates were coated with fibronectin (10 μg/ml), EHS-laminin (20 μg/ml), human placenta laminin (1 μg/ml), human recombinant laminin-5 (0.5 μg/ml) or poly-D-lysine (30 μg/ml), incubated at 37 °C for 1 h or at 4 °C overnight, washed with PBS (pH 7.4) and overlaid with 1% (w/v) heat-denatured BSA at 37 °C for 1 h. Collagen I- and collagen IV-coated plates were purchased from BD Biosciences and were overlaid with BSA as described above. To obtain NEU3 stable transfectants, a NEU3 expression vector was constructed by subcloning the ORF (open reading frame) of human NEU3 cDNA into the pCEP4 expression plasmid vector (Invitrogen). The vector was then transfected into DLD-1 cells by Effectene™ (Qiagen). Positive clones were selected under hygromycin (250 μg/ml). For transient transfection, an expression plasmid, constructed by inserting HA-tagged NEU3 cDNA into the pCAGGS expression vector [19], was transfected transiently as described above. To determine sialidase activity, cells were sonicated in 9 vol. of PBS containing 1 mM EDTA and 0.5 mM PMSF, leupeptin and pepstatin, and centrifuged at 1000 g for 10 min. The supernatant (crude extract) was then used for the measurement of sialidase activity at pH 4.6 with mixed gangliosides from bovine brain (Sigma) as a substrate in the presence of Triton X-100. The released sialic acid was determined by the modified thiobarbituric acid method as described previously [13]. Protein concentrations were determined by dye-binding assay (Bio-Rad Laboratories). A unit of activity was defined as the amount of enzyme that cleaved 1 nmol of sialic acid.

Flow-cytometric analyses

Subconfluent cells were harvested by trypsinization, washed with PBS, resuspended in PBS containing 0.5% BSA and incubated with monoclonal anti-integrin antibodies or control mouse IgG (Santa Cruz Biotechnology) in 0.5% BSA for 30 min on ice. After washing twice with PBS, cells were incubated with FITC-conjugated secondary antibodies in 0.5% BSA for 30 min on ice. Cells were then washed twice with PBS and cell-surface integrins were determined using a flow cytometer (BD Biosciences).

Cell-adhesion assays

For cell-adhesion assays, a Cystal Violet colorimetric method was employed [20]. Briefly, subconfluent cells were harvested by trypsinization, washed and suspended in serum-free medium containing 0.1% BSA at 1×106 cells/ml, then plated on 96-well cell-culture plates coated with ECM and incubated at 37 °C for 15–60 min. Cell-culture plates were washed with PBS to remove unbound cells, fixed with 70% ethanol at 4 °C for 15 min, stained with 0.1% Crystal Violet (Sigma) at room temperature for 25 min and washed twice with distilled water. Crystal Violet in adherent cells was eluted with 10% (v/v) acetic acid, and cell adhesion was determined by A550 on a microplate reader (Corona Electric). In cell-adhesion-inhibition assays, suspended cells were incubated with 5 μg/ml neutralizing anti-integrin antibodies at 37 °C for 30 min before plating. In some experiments, cell-adhesion assays were performed at 4 °C to determine integrin α6β4-mediated cell adhesion [21]. To examine the effects of ganglioside GM3 on cell adhesion, cells were untreated or pretreated with GM3 (Alexis Biochemicals) at 50 μM in conditioned medium for 24 h at 37 °C and were assayed for cell adhesion.

Cell-proliferation and DNA-synthesis assays

Cell growth rate was measured using a modified MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay. Subconfluent cells were harvested, washed and suspended in serum-free medium at 3×104 cells/ml. Cells were seeded on to 96-well ECM-coated cell-culture plates at 100 μl/well and incubated at 37 °C. After 0–96 h, WST-1 reagent was added, incubated for 1 h at 37 °C, and formazan produced by live cells was measured with a microplate reader at A450 (reference A630). DNA synthesis was determined by BrdU (bromodeoxyuridine) incorporation using a BrdU Labeling and Detection kit III (Roche Diagnostics). Cells, seeded on 96-well plates as above, were incubated at 37 °C for 16 h, and BrdU was then added to the cell culture. After incubation for a further 4 h, incorporated BrdU was detected according to the manufacturer's instructions.

Immunoprecipitation and immunoblotting

Subconfluent cells maintained in serum-free medium for 20–24 h were harvested and suspended in serum-free medium under rotation at 37 °C for 45 min. Cells were allowed to adhere for 15–60 min to cell-culture dishes coated with ECM as described above. After incubation, dishes were rinsed with PBS to remove unattached cells and the adherent cells were extracted with modified RIPA buffer [50 mM Hepes (pH 7.5), 150 mM NaCl, 1% Nonidet P40, 2 mM EDTA, 7.5 μg/ml aprotinin, 10 μg/ml leupeptin, 10 mM NaF, 2 mM orthovanadate, 0.25% sodium deoxycholate and 2 mM PMSF] for 30 min on ice. Suspended cells without adhesion were used as the controls. Lysates were briefly sonicated and precleared with centrifugation at 1000 g for 10 min before use. Protein-matched samples were added to anti-(integrin β1) or -(integrin β4) antibodies and incubated at 4 °C for 30 min (integrin β4) or 2 h (integrin β1). Protein G–Sepharose (Amersham Biosciences) was then added and immunoprecipitation was continued for another 3 h (integrin β4) or overnight (integrin β1) at 4 °C. The immunoprecipitates were separated by SDS/PAGE and were transferred on to PVDF membranes (Amersham Biosciences). Transferred proteins were detected with specific antibodies by ECL® (enhanced chemiluminescence) (Amersham Biosciences) and a CCD (charged coupled device) imaging system (Bio-Rad Laboratories). Densitometric analyses were performed with Scion Image and Quantity One software (Bio-Rad Laboratories). In the immunoprecipitation of NEU3 with the anti-(integrin β4) antibody, 24 h after transient transfection with HA-tagged NEU3, cells were cultured for a further 24 h under serum depletion and then plated on to laminin-5. The cells harvested were lysed and subjected to immunoprecipitation with the anti-(integrin β4) antibody. NEU3 and Grb2 were detected in the immunoprecipitates with anti-HA and anti-Grb2 antibodies respectively. Endogenous NEU3 was detected with an HRP-conjugated anti-NEU3 antibody.

TLC

The glycolipid pattern was analysed by TLC. From 107 cells, glycolipids were extracted with 2 ml of propan-2-ol/hexane/water (11:5:4, by vol.) and hydrolysed phospholipids with 0.1 M NaOH/methanol. After desalting with a SEP-PAK C18 cartridge, total lipid extracts were applied to DEAE–Sephadex A25 minicolumns. Neutral glycolipids were eluted with chloroform/methanol/water (15:30:4, by vol.) and acidic glycolipids with chloroform/methanol/2 M sodium acetate (15:30:4, by vol.). After dialysis, equal amounts of each sample were applied on to HPLC plates (Baker). Neutral glycolipids were separated by chromatography in a solvent system of chloroform/methanol/0.02% aqueous CaCl2 (60:40:9, by vol.), and acidic glycolipids by chromatography in chloroform/methanol/0.02% aqueous CaCl2 (60:35:8, by vol.). Both were visualized with orcinol/H2SO4. TLC immunostaining was performed using monoclonal anti-GM3 antibodies and an avidin–biotin immunoperoxidase staining kit (Vector).

RESULTS

NEU3 promotes cell adhesion to laminins

Human colon cancer DLD-1 cells were stably transfected with NEU3 cDNA (Figure 1a), and the clones with the highest (NEU3-8) and intermediate (NEU3-4) expression levels were examined routinely for cell adhesion and growth. When integrin expression was compared between NEU3-transfected and control cells by flow-cytometric analysis with their respective antibodies, the cells exhibited no significant difference in the levels of integrins α3, α5, α6, β1 and β4 (Figure 1b), irrespective of the introduction of the NEU3 gene. Examination of adhesion on four ECM proteins showed that stably NEU3-transfected cells exhibited an increase by 214% when plated on EHS-laminin, but a decrease with fibronectin, collagen I and collagen IV, compared with control cells (Figure 2a). Adhesion to the matrix proteins reached a maximum at 30 min and remained almost constant until 60 min (results not shown). As it is known that EHS-laminin purified from the mouse tumour contains only laminin 1, we tested two other laminin isoforms, human placenta laminin, composed mainly of laminin-10 and -11, and laminin-5, purified from cells expressing the recombinant protein [17]. The latter laminin has often been reported to be highly expressed in carcinomas [3]. The attachment to all of the three isoforms was increased in NEU3-overexpressing cells compared with control cells (Figure 2b). When DLD-1 cells and another colon carcinoma cell line, HCT-116 cells, were transiently transfected with the pCAGGS vector containing NEU3 and the cells had increased sialidase activity (4.0- and 5.7-fold respectively), adhesion was largely similar to that of the stable NEU3-transfected DLD-1 cells (Figure 2c), indicating that the changes in adhesion activity were due to NEU3 overexpression. To check which integrin was involved in the attachment of each laminin form, cell-adhesion-inhibition assays were performed using antibodies inhibiting integrin adhesion. Adhesion to EHS-laminin was dramatically decreased by anti-(integrin β1) and anti-(integrin α6) antibodies, but only slightly by antibodies to integrins α3 and β4 (Figure 3a). Adhesion to laminin-5 was inhibited by antibodies against integrins α3, β1, β4 and α6 (Figure 3b). Although the levels of inhibition were generally not remarkable, almost all of the activity was decreased with the anti-(integrin β4) antibody at 4 °C (Figure 3c), as the cold conditions excluded the adhesion activity due to integrin β1 [21]. Increased adhesion due to NEU3 was almost prevented by treatment with the adhesion-inhibitory antibodies. These data indicate that cell attachment on EHS-laminin and laminin-5 is essentially mediated by integrin α6β1 and by integrins α3β1, α6β1 and α6β4 respectively, consistent with the observations on integrin receptors specific for these laminins [22,23], and that the effects of NEU3 overexpression on adhesion are dependent on matrix substrates.

Figure 1
Sialidase activity level of NEU3-transfected DLD-1 cells and their flow-cytometric analyses of integrin subunits
Figure 2
Effects of NEU3 on cell adhesion on laminins, fibronectin and collagens I and IV
Figure 3
Effects of anti-integrin antibodies on cell adhesion

NEU3 promotes cell proliferation on laminins

Results for cell growth on matrix proteins, as examined by MTT assay, are shown in Figure 4(a). Similar to the pattern of adhesion, cell proliferation was enhanced in the transfectants on EHS-laminin and laminin-5, but was decreased in cells on fibronectin. To confirm this observation, BrdU incorporation into DNA was measured (Figure 4b). Uptake in the cells on laminins was stimulated by NEU3 overexpression, whereas a decrease was again apparent with fibronectin. When the cells were treated with antibodies against specific integrins, the anti-(integrin β1) antibody clearly inhibited cell proliferation on laminin-5 (Figure 4c), whereas the anti-(integrin β4) antibody (ASC-8) affected this to a lesser extent. Since there is a possibility that the anti-(integrin β4) antibody may be inhibitory only for cell adhesion, we used the function-activating anti-(integrin β4) antibody (3E1) (Figure 4d). Proliferation of the treated mock transfectants was 144% of that of control-antibody-treated cells and the value of NEU3 transfectants was 178% of the control, indicating that integrin β4 was actually involved in the promotion of proliferation by NEU3 transfection.

Figure 4
Differential effects of NEU3 on cell proliferation of cells on laminins and fibronectin

NEU3 promotes integrin-mediated signalling on laminins and facilitates the formation of a Shc–Grb2 complex

To investigate the molecular mechanisms underlying the differential effects of NEU3 on laminins and fibronectin, the phosphorylation levels of molecules involved in integrin-mediated signalling were evaluated. As shown in Figure 5(a), tyrosine phosphorylation of FAK, which is a mediator of integrin signalling that is overexpressed in tumour cells [24,25], was increased by attachment to EHS-laminin, having a maximal stimulation at approx. 15–30 min. In NEU3 transfectants, adhesion caused further stimulation of phosphorylation compared with that in mock transfectants. This phenomenon was observed in transfectants expressing different levels of NEU3 (Figure 5b). At 15 min after adhesion to laminin-5 or EHS-laminin, the level of phosphorylation was also much higher in NEU3 transfectants than in control cells. In contrast, no significant stimulation was found with fibronectin, even when accompanied by NEU3 overexpression (Figure 5c). Human placenta laminin, the predominant ligand for α3β1 and α6β1 integrins [26], exhibited an activation pattern similar to EHS-laminin (results not shown).

Figure 5
Effects of NEU3 on the phosphorylation of FAK and ERK upon adhesion of cells on laminins and fibronectin

We then evaluated the tyrosine phosphorylation of Shc, an adaptor protein in another major tyrosine-kinase-dependent pathway activated by integrins which is often constitutively activated in tumours [27]. The level was relatively high, even without adhesion, and was increased by NEU3 transfection in the cells on laminin-5, but the cells on EHS-laminin and fibronectin had decreased Shc phosphorylation (Figure 5d). As it has been proposed that integrins activate ERK through FAK or Shc, the phosphorylation of ERK was examined in cells kept in suspension or plated on to EHS-laminin. As shown in Figure 5(e), ERK was phosphorylated by adhesion to laminin in mock transfectants and to a larger extent in the two independent NEU3-transfected clones, with the extent of activation being enhanced in the transfectants with higher NEU3 activity. The cells on laminin-5 had ERK phosphorylation similar to that on EHS-laminin, whereas adhesion to fibronectin did not cause significant phosphorylation (Figure 5f). These findings indicate that NEU3 overexpression stimulates ERK phosphorylation through the FAK and Shc pathways by adhesion to laminin-5; a pathway different from that induced by EHS-laminin which had hardly any Shc phosphorylation. Furthermore, adhesion to fibronectin resulted in no significant phosphorylation, but, instead, inhibited the phosphorylation of these molecules. It should be noted that ERK phosphorylation in the cells on collagen IV was unaffected, which was different from cells on fibronectin having decreased phosphorylation. Considering the differential effects of the two laminins, we then examined how the integrin β1 and β4 receptors for these matrix proteins contributed to the integrin-mediated signalling, since integrins α3β1, α6β4 and α6β1 have been shown to be specific receptors for laminin-5 and integrin α6β1 for EHS-laminin [22,23]. As shown in Figure 6(a), serine/threonine phosphorylation of integrin β1 was stimulated in the NEU3 transfectants grown on the two laminins compared with the control cells, but again the phosphorylation was not increased by adhesion to fibronectin, although elevated phosphorylation was observed even without cell attachment in all of the cases. ILK, an intracellular serine/threonine kinase interacting with integrin β1 [28], was then immunoprecipitated with an anti-ILK antibody, and the level of threonine phosphorylation was estimated. Consistent with integrin β1 phosphorylation, an increase in phosphorylation of ILK was observed with NEU3 overexpression in cells attached to the laminins, whereas this was decreased in cells on fibronectin (Figure 6b). Next, integrin β4 phosphorylation was analysed by immunoprecipitation of cell lysates with an anti-(integrin β4) antibody, followed by immunoblotting with an anti-phosphotyrosine antibody. Integrin β4 was found to be phosphorylated effectively on adhesion to laminin-5, and the level was much higher after NEU3 transfection; however, phosphorylation was inhibited on EHS-laminin (Figure 6c). To verify the differential effects of NEU3 on integrin β4 phosphorylation between the two laminins, the immunoprecipitates were analysed for recruitment of the related adaptors, Shc and Grb2, in response to adhesion. Integrin β4 activation was accompanied by recruitment of Shc and its association with Grb2, as reported previously [29], and activation was prominent in NEU3 transfectants (Figure 6c), consistent with the level of Shc phosphorylation (Figure 5d). Additionally, exogenous NEU3 was detected in the immunoprecipitates with the anti-(integrin β4) antibody (Figure 6d) under conditions where neither the NEU3 protein band in the cells treated with control IgG nor the transferrin receptor, expressed abundantly (results not shown), was detected, suggesting that the presence of NEU3 is possibly specific for this event with integrin β4. To strengthen the effect of NEU3, an attempt to detect endogenous NEU3 in the immunoprecipitates with the anti-(integrin β4) antibody was determined using Colo 205 cells, which have relatively high NEU3 expression. Endogenous NEU3 was also detected as a faint band, but reproducibly in the immunoprecipitates (Figure 6e). Although the co-immunoprecipitation of NEU3, expressed either endogenously or exogenously, with integrin β4 was not adhesion- dependent, recruitment of NEU3 may create an environment in which it is readily accessible to integrin β4 to activate signalling. Taken together, the data indicate that NEU3 overexpression promoted integrin-β4-mediated signalling on laminin-5, in addition to integrin β1 activation, leading to greater activation of FAK and Shc pathways and subsequent ERK phosphorylation than observed on EHS-laminin only. Unlike these laminins, fibronectin negatively influenced integrin activation due to NEU3.

Figure 6
Effects of NEU3 on the phosphorylation of integrin β1, ILK and integrin β4 upon adhesion of cells on laminins and fibronectin

Possible involvement of gangliosides in cell adhesion

Finally, we examined the possible mechanisms of an alteration in integrin-mediated signalling caused by NEU3 overexpression. To determine whether glycolipids produced as the result of NEU3 enzyme activity actually affect cell adhesion, glycolipids from DLD-1 cells employed in the experiments were analysed by TLC. In addition to a slight increase in lactosylceramide in neutral glycolipid fractions (results not shown), NEU3 transfectants had a significant decrease in GM3 gangliosides compared with control cells in the acidic glycolipid fractions (Figure 7a), which was confirmed by TLC immunostaining using an monoclonal anti-GM3 antibody (M2590; Figure 7b). Therefore we incubated cells with GM3 in culture medium containing 10% (v/v) FBS for 24 h and measured cell adhesion on EHS-laminin, laminin-5 and fibronectin. As shown in Figure 7(c), GM3 significantly inhibited adhesion of cells on EHS-laminin, but essentially had no effect on laminin-5. However, addition of GM3 had a tendency to increase adhesion on fibronectin. The results indicate that a decrease in GM3 is a possible mechanism for NEU3-induced stimulation of adhesion to EHS-laminin and subsequent activation of integrin-mediated signalling. However, a change in the level of GM3 was not effective for adhesion to laminin-5, whereas GM3 had the opposite effect in cells on fibronectin by increasing adhesion. In cells on laminin-5, acceleration of adhesion and the subsequent signalling might be partially due to positive regulation by interaction of NEU3 with the Shc–Grb2 complex as shown in Figure 6(c), although the participation of a small amount of an unidentified glycolipid product(s) cannot be excluded.

Figure 7
Effect on the level of GM3 (a and b) and GM3-mediated cell adhesion (c) in NEU3-transfected cells

DISCUSSION

The present study provides the first evidence that plasma-membrane-associated sialidase (NEU3) promotes cell adhesion to laminins, integrin-mediated signalling to ERK and subsequent activation of cell proliferation, but attenuates adhesion to fibronectin and its related signalling. Among the three types of laminins tested, only laminin-5, a major ligand for integrin α6β4, contributed to Shc phosphorylation in addition to FAK phosphorylation; NEU3 enhancing both adhesion-dependent and -independent tyrosine phosphorylation of integrin β4 and Shc, recruitment of Grb2 and ERK phosphorylation. Although the distinct roles of Shc and FAK in ERK activation are not fully understood, they have been suggested to participate in early and persistent events respectively [30]. NEU3 overexpression may thus contribute to enhance and sustained ERK activation through Shc and FAK signalling when cells are attached to laminin-5, leading to adhesion-dependent cell proliferation. ERK phosphorylation on EHS-laminin appeared to be relatively modest (Figure 5f) compared with the magnitude of enhancement of cell adhesion and proliferation, but tyrosine phosphorylation of integrin β1 was more evident than on laminin-5 (Figure 6) and this may lead to the enhanced adhesion and proliferation via not only ERK, but also other pathways, including PI3K (phosphoinositide 3-kinase)/Akt, that are responsible for regulation of cell proliferation and survival. In fact, Akt phosphorylation was activated by NEU3-overexpressing cells (results not shown). In the present study, attachment to laminin-5 was also found to increase cell motility, which was largely inhibited by anti-(integrin β1) antibodies, but with little effects when an anti-(integrin β4) antibody (ASC-8) was used (results not shown). It is still possible that the antibody used for the latter is inhibitory only for adhesion, but not for cell proliferation and cell motility in this cell system. Whatever the case, the results indicate that NEU3 differentially regulates cell adhesion and consequent signalling dependent on the individual matrix substrate, mediated by integrin α6β1 for EHS-laminin, by integrins α3β1, α6β1 and α6β4 for laminin-5 and possibly by integrin α5β1 for fibronectin. A schematic model for the hypothetical role of NEU3 in integrin-mediated signalling is shown in Figure 8.

Figure 8
Model of the hypothetical role of NEU3 in integrin-mediated signalling

Our present results suggest further that GM3 depletion by NEU3 may be one of the causes of stimulation of cell adhesion and proliferation mediated by integrins α3β1 and α6β1 through increased integrin β1 phosphorylation, but suppression of integrin α5β1-mediated signalling (Figure 6). With or without yet unidentified NEU3 product(s), the NEU3 molecule itself could interact with integrin α6β4 and promote Shc phosphorylation and recruitment of Grb2 through integrin β4 phosphorylation (Figure 6). This is in line with our previous finding that NEU3 is localized in membrane microdomains, caveolae or rafts and interacts with signalling molecules such as caveolin-1 [18] and Grb2 [31] in insulin signalling. Furthermore, the compartmentalization of integrin α6β4 in lipid rafts has been shown to be required for efficient signalling to ERK in keratinocytes [32]; NEU3 possibly being accessible to integrin α6β4 and then promoting Shc phosphorylation and recruitment of Grb2. In this context, it is intriguing to know whether NEU3 affects HGF (hepatocyte growth factor)-induced signal transduction via the Met receptor, since the signalling has been proposed to be associated with integrin α6β4, leading to invasion of carcinoma cells [33]. Our preliminary results have shown that NEU3 activated HGF-dependent tyrosine phosphorylation of Met receptor in DLD-1 cells (results not shown).

In direct contrast with our present results, there have been several studies reporting that adhesion to fibronectin is promoted by GM3 depletion in SSC cells [10] and IdI cells [8]. However, other reports have described that GM3 depletion inhibits cell adhesion to fibronectin in rat hepatoma cells [34] and mouse mammary carcinoma cells [7]. In the present study, we have shown a reduction in ILK phosphorylation by cells on fibronectin, in contrast with its activation by GM3 depletion in SSC cells [35]. It is necessary to elucidate why and how NEU3 displays differential effects, and this presumably occurs through recognition of individual integrin receptors. In this context, it is of interest that increased adhesion on laminins and the decrease on fibronectin by NEU3 overexpression was also observed in oral squamous cell carcinoma cells HSC-2 (K. Kato, K. Shiga and T. Miyagi, unpublished work). This indicates that NEU3 might induce these phenomena independently of cell type, via modulation of signalling by interacting with signalling molecules, such as integrin β4, in addition to changing ganglioside patterns.

We have found previously a remarkable increase in expression of NEU3 in colon cancer tissues compared with adjacent non-cancerous tissues at both the mRNA and enzyme activity levels [16]. Moreover, the present results clearly indicate that NEU3 is indeed involved in activation of signalling molecules, including FAK [24,25], ILK [28], Shc [27], integrin β4 [3,36] and also Met [33], often up-regulated in carcinogenesis. Among matrix proteins, laminins have been implicated in an increase in the malignant phenotype of tumour cells. Neo-expression of laminin-5 is associated with proliferation of carcinoma cells and this ECM element often accumulates in invading edges of carcinomas [3]. Integrins α3β1 and α6β4 are cell-surface receptors acting with laminin-5. By contrast, fibronectin has been shown to reduce progression of carcinomas [37,38]. Since there were no significant differences in expression level of integrin receptors between NEU3 transfectants and control cells in the present study, NEU3 might function distinctly with individual integrins. In fact, NEU3 does not activate, but rather attenuates, integrin-α5β1-mediated signalling. From the present results, elevated expression of NEU3 in colon cancer may cause tumour progression through further activation of molecules that are up-regulated on adhesion to laminins which usually accumulate in this type of cancer. In contrast, NEU3 might negatively regulate signalling on fibronectin, resulting in suppression of cell adhesion, proliferation and migration. It should be borne in mind that NEU3 elevation is characteristic in cancer and found in a wide spectrum of lesions, including tumours of the digestive system (K. Shiga, K. Kato, T. Wada and T. Miyagi, unpublished work). The molecular mechanisms and significance of increased expression of NEU3 in cancer could be targeted with the hope of providing valuable information for diagnosis and therapy.

Acknowledgments

We thank Ms Setsuko Moriya for expert technical assistance. This study was supported in part by Grants-in-Aid from Kurokawa Cancer Research Foundation and by a Grant-in-Aid of The Japan Medical Association.

References

1. Hynes R. O. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673–687. [PubMed]
2. Calderwood D. A. Integrin activation. J. Cell Sci. 2004;117:657–666. [PubMed]
3. Lohi J. Laminin-5 in the progression of carcinomas. Int. J. Cancer. 2001;94:763–767. [PubMed]
4. Engbring J. A., Kleinman H. K. The basement membrane matrix in malignancy. J. Pathol. 2003;200:465–470. [PubMed]
5. Hakomori S., Yamamura S., Handa K. Signal transduction through glyco (sphingo) lipids. Introduction and recent studies on glyco (sphingo) lipid-enriched microdomains. Ann. N.Y. Acad. Sci. 1998;845:1–10. [PubMed]
6. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo (glyco) lipid metabolism. Cancer Res. 1996;56:5309–5318. [PubMed]
7. Zheng M., Fang H., Tsuruoka T., Tsuji T., Sasaki T., Hakomori S. Regulatory role of GM3 ganglioside in α5β1 integrin receptor for fibronectin-mediated adhesion of FUA169 cells. J. Biol. Chem. 1993;268:2217–2222. [PubMed]
8. Kawakami Y., Kawakami K., Steelant W. F., Ono M., Baek R. C., Handa K., Withers D. A., Hakomori S. Tetraspanin CD9 is a ‘proteolipid’ and its interaction with α3 integrin in microdomain is promoted by GM3 ganglioside, leading to inhibition of laminin-5-dependent cell motility. J. Biol. Chem. 2002;277:34349–34358. [PubMed]
9. Wang X. Q., Sun P., Paller A. S. Ganglioside GM3 blocks the activation of epidermal growth factor receptor induced by integrin at specific tyrosine sites. J. Biol. Chem. 2003;278:48770–48778. [PubMed]
10. Wang X. Q., Sun P., Paller A. S. Ganglioside GM3 inhibits matrix metalloproteinase-9 activation and disrupts its association with integrin. J. Biol. Chem. 2003;278:25591–25599. [PubMed]
11. Monti E., Preti A., Venerando B., Borsani G. Recent development in mammalian sialidase molecular biology. Neurochem. Res. 2002;27:649–663. [PubMed]
12. Miyagi T., Kato K., Ueno S., Wada T. Aberrant expression of sialidase in cancer. Trends Glycosci. Glycotechnol. 2004;92:371–381.
13. Miyagi T., Wada T., Iwamatsu A., Hata K., Yoshikawa Y., Tokuyama S., Sawada M. Molecular cloning and characterization of a plasma membrane-associated sialidase specific for gangliosides. J. Biol. Chem. 1999;274:5004–5011. [PubMed]
14. Wada T., Yoshikawa Y., Tokuyama S., Kuwabara M., Akita H., Miyagi T. Cloning, expression and chromosomal mapping of a human ganglioside sialidase. Biochem. Biophys. Res. Commun. 1999;261:21–27. [PubMed]
15. Hasegawa T., Yamaguchi K., Wada T., Takeda A., Itoyama Y., Miyagi T. Cloning, expression, and chromosomal mapping of a human ganglioside sialidase. J. Biol. Chem. 2000;275:8007–8015. [PubMed]
16. Kakugawa Y., Wada T., Yamaguchi K., Yamanami H., Ouchi K., Sato I., Miyagi T. Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Proc. Natl. Acad. Sci. U.S.A. 2002;99:10718–10723. [PMC free article] [PubMed]
17. Kariya Y., Ishida K., Tsubota Y., Nakashima Y., Hirosaki T., Ogawa T., Miyazaki K. Efficient expression system of human recombinant laminin-5. J. Biochem. (Tokyo) 2002;132:607–612. [PubMed]
18. Wang Y., Yamaguchi K., Wada T., Hata K., Zhao X., Fujimoto T., Miyagi T. A close association of the ganglioside-specific sialidase Neu3 with caveolin in membrane microdomains. J. Biol. Chem. 2002;277:26252–26259. [PubMed]
19. Niwa H., Yamamura K., Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991;108:193–200. [PubMed]
20. Orian-Rousseau V., Aberdam D., Rousselle P., Messent A., Gavrilovic J., Meneguzzi G., Kedinger M., Simon-Assmann P. Human colonic cancer cells synthesize and adhere to laminin-5. Their adhesion to laminin-5 involves multiple receptors among which is integrin α2β1. J. Cell Sci. 1998;111:1193–2004. [PubMed]
21. Russell A. J., Fincher E. F., Millman L., Smith R., Vela V., Waterman E. A., Dey C. N., Guide S., Weaver V. M., Marinkovich M. P. α6β4 integrin regulates keratinocyte chemotaxis through differential GTPase activation and antagonism of α3β1 integrin. J. Cell Sci. 2003;116:3543–3556. [PubMed]
22. Niessen C. M., Hogervorst F., Jaspars L. H., de Melker A. A., Delwel G. O., Hulsman E. H., Kuikman I., Sonnenberg A. The α6β4 integrin is a receptor for both laminin and kalinin. Exp. Cell Res. 1994;211:360–367. [PubMed]
23. Rousselle P., Aumailley M. Kalinin is more efficient than laminin in promoting adhesion of primary keratinocytes and some other epithelial cells and has a different requirement for integrin receptors. J. Cell Biol. 1994;125:205–214. [PMC free article] [PubMed]
24. Weiner T. M., Liu E. T., Craven R. J., Cance W. G. Expression of focal adhesion kinase gene and invasive cancer. Lancet. 1993;342:1024–1025. [PubMed]
25. Owens L. V., Xu L., Craven R. J., Dent G. A., Weiner T. M., Kornberg L., Liu E. T., Cance W. G. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res. 1995;55:2752–2755. [PubMed]
26. Kikkawa Y., Sanzen N., Fujiwa H., Sonnenberg A., Sekiguchi K. Integrin binding specificity of laminin-10/11: laminin-10/11 are recognized by α3β1, α6β1 and α6β4 integrins. J. Cell Sci. 2000;113:869–876. [PubMed]
27. Pelicci G., Lanfrancone L., Salcini A. E., Romano A., Mele S., Grazia Borrello M., Segatto O., Di Fiore P. P., Pelicci P. G. Constitutive phosphorylation of Shc proteins in human tumors. Oncogene. 1995;11:899–907. [PubMed]
28. Persad S., Dedhar S. The role of integrin-linked kinase (ILK) in cancer progression. Cancer Metastasis Rev. 2003;22:375–384. [PubMed]
29. Mainiero F., Pepe A., Wary K. K., Spinardi L., Mohammadi M., Schlessinger J., Giancotti F. G. Signal transduction by the α6β4 integrin: distinct β4 subunit sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes. EMBO J. 1995;14:4470–4481. [PMC free article] [PubMed]
30. Barberis L., Wary K. K., Fiucci G., Liu F., Hirsch E., Brancaccio M., Altruda F., Tarone G., Giancotti F. G. Distinct roles of the adaptor protein Shc and focal adhesion kinase in integrin signaling to ERK. J. Biol. Chem. 2000;275:36532–36540. [PubMed]
31. Sasaki T., Hata H., Suzuki S., Sawada M., Wada T., Tateno H., Obinata M., Suzuki Y., Miyagi T. Overexpression of plasma membrane-associated sialidase attenuates insulin signaling in transgenic mice. J. Biol. Chem. 2003;278:27896–27902. [PubMed]
32. Gagnoux-Palacios L., Dans M., van't Hof W., Mariotti A., Pepe A., Meneguzzi G., Resh M. D., Giancotti F. G. Compartmentalization of integrin α6β4 signaling in lipid rafts. J. Cell Biol. 2003;162:1189–1196. [PMC free article] [PubMed]
33. Trusolino L., Bertotti A., Comoglio P. M. A signaling adaptor function for α6β4 integrin in the control of HGF-dependent invasive growth. Cell. 2001;107:643–654. [PubMed]
34. Barletta E., Mugnai G., Ruggieri S. Complex gangliosides modulate the integrin-mediated adhesion in a rat hepatoma cell line. Biochem. Biophys. Res. Commun. 1993;192:214–222. [PubMed]
35. Wang X. Q., Sun P., Paller A. S. Inhibition of integrin-linked kinase/protein kinase B/Akt signaling: mechanism for ganglioside-induced apoptosis. J. Biol. Chem. 2001;276:44504–44511. [PubMed]
36. Dajee M., Lazarov M., Zhang J. Y., Cai T., Green C. L., Russell A. J., Marinkovich M. P., Tao S., Lin Q., Kubo Y., Khavari P. A. NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature (London) 2003;421:594–595. [PubMed]
37. Akiyama S. K., Olden K., Yamada K. M. Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev. 1995;14:173–189. [PubMed]
38. Taverna D., Ullman-Cullere M., Rayburn H., Bronson R. T., Hynes R. O. A test of the role of α5 integrin/fibronectin interactions in tumorigenesis. Cancer Res. 1998;58:848–853. [PubMed]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...